Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, immune‑mediated neurological disorder that causes progressive weakness and impaired sensory function in the arms and legs. It is considered the chronic counterpart of Guillain‑Barré syndrome (GBS). In CIDP, the body’s immune system mistakenly attacks the myelin sheath—the protective covering of peripheral nerves—leading to slowed or blocked nerve signal transmission.¹ The disease course can be relapsing‑remitting, steadily progressive, or monophasic, and symptoms may develop over weeks to months.

Symptoms Checklist

Typical manifestations of CIDP include:

• ✔️ Symmetrical muscle weakness, usually beginning in the legs and later affecting the arms
• ✔️ Numbness or tingling (paresthesia) in the hands and feet
• ✔️ Decreased or absent reflexes (areflexia)
• ✔️ Fatigue and difficulty walking or climbing stairs
• ✔️ Loss of fine motor skills (e.g., buttoning shirts)
• ✔️ Sensory loss that may progress to a “glove‑and‑stocking” distribution
• ✔️ Pain or burning sensations in the extremities
• ✔️ Autonomic symptoms (e.g., abnormal sweating, blood pressure fluctuations) in a minority of patients

Risk Factors

While the exact cause of CIDP is unknown, certain factors appear to increase susceptibility:

• Age: Most commonly diagnosed in adults 40‑60 years old, but can occur at any age
• Sex: Slight male predominance in some studies
• History of autoimmune diseases (e.g., lupus, rheumatoid arthritis, inflammatory bowel disease)
• Recent infections or vaccinations (temporal association, not causation)
• Family history of other autoimmune disorders
• Diabetes mellitus – may coexist and complicate diagnosis

Diagnosis

Diagnosing CIDP requires a combination of clinical evaluation, electrophysiological testing, and laboratory studies:

1. Clinical criteria – progressive or relapsing weakness and sensory loss over ≥8 weeks.
2. Electrodiagnostic studies (nerve conduction studies & electromyography) – show demyelination patterns such as slowed conduction velocity, prolonged distal latencies, and conduction block.²
3. Lumbar puncture – cerebrospinal fluid (CSF) often reveals elevated protein with normal cell count (albuminocytologic dissociation).
4. Blood tests – rule out diabetes, vitamin deficiencies, and other mimicking conditions; may include autoimmune panels.
5. Magnetic resonance imaging (MRI) – can demonstrate nerve root or plexus enhancement.
6. Biopsy (rare) – nerve or skin biopsy may be performed when diagnosis remains uncertain.

Treatment Options

Treatment aims to suppress the abnormal immune response, improve nerve function, and maintain quality of life.

First‑line medical therapies

• Corticosteroids (e.g., prednisone, prednisolone) – often the initial choice; tapering schedules are individualized.³
• Intravenous immunoglobulin (IVIG) – administered over 2‑5 days; effective in many patients, especially those who cannot tolerate steroids.
• Plasma exchange (PLEX) – removes circulating antibodies; typically 4‑6 exchanges over 1‑2 weeks.

Second‑line / adjunctive therapies

• Immunosuppressants: azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate.
• Biologic agents: rituximab (anti‑CD20) – considered for refractory cases or patients with associated autoimmune disease.

Supportive & home‑based measures

• Physical therapy – strength training, gait training, and balance exercises.
• Occupational therapy – adaptive devices for dressing, writing, and daily tasks.
• Pain management – NSAIDs, gabapentin, pregabalin, or duloxetine for neuropathic pain.
• Assistive devices – braces, canes, walkers, or wheelchairs as needed.
• Nutrition & hydration – adequate protein intake supports nerve repair; stay well‑hydrated.

Prevention

Because CIDP is an autoimmune condition with no known single cause, primary prevention is limited. However, risk can be reduced by:

• Managing underlying autoimmune diseases aggressively.
• Controlling diabetes and other metabolic disorders that may exacerbate neuropathy.
• Maintaining a healthy lifestyle (balanced diet, regular exercise, smoking cessation) to support immune regulation.
• Promptly treating infections and discussing vaccine timing with a neurologist if you have a known autoimmune predisposition.

Living With CIDP

Long‑term management focuses on maintaining function and preventing complications:

• Regular follow‑up with a neurologist to monitor disease activity and medication side effects.
• Exercise program – low‑impact activities (e.g., swimming, stationary cycling) improve endurance without over‑stress.
• Energy conservation – plan tasks, use assistive tools, and schedule rest periods.
• Skin care – inspect feet daily for injuries, especially if sensation is reduced.
• Psychosocial support – counseling, support groups, or online communities can help cope with chronic illness.
• Medication adherence – never stop steroids or IVIG abruptly without medical guidance.

When to Seek Emergency Care

Although CIDP is usually chronic, sudden worsening may signal a medical emergency:

• Rapid progression of weakness leading to difficulty breathing or swallowing.
• Sudden loss of bladder or bowel control.
• Severe, unrelenting pain unresponsive to usual medications.
• Signs of infection at IVIG or catheter sites (fever, redness, swelling).
• Adverse reactions to treatment (e.g., anaphylaxis after IVIG).

If any of these occur, call 911 or go to the nearest emergency department.

References:
1. Mayo Clinic. “Chronic inflammatory demyelinating polyneuropathy (CIDP).” https://www.mayoclinic.org/diseases-conditions/cidp
2. National Institute of Neurological Disorders and Stroke (NINDS). “CIDP – Diagnosis.” https://www.ninds.nih.gov/Disorders/All-Disorders/Chronic-Inflammatory-Demyelinating-Polyneuropathy-Information-Page
3. Cleveland Clinic. “CIDP Treatment Options.” https://my.clevelandclinic.org/health/diseases/16871-chronic-inflammatory-demyelinating-polyneuropathy
4. Johns Hopkins Medicine. “Chronic Inflammatory Demyelinating Polyneuropathy.” https://www.hopkinsmedicine.org/health/conditions-and-diseases/chronic-inflammatory-demyelinating-polyneuropathy
5. CDC. “Peripheral Neuropathy.” https://www.cdc.gov/neurology/peripheral-neuropathy.html